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ABSTRACT

Meng-Chieh Chen. M.S., Purdue University, December 2014. New Strategies to Reveal
Protein Candidates in Protein-Protein Interactome Study. Major Professor: Weiguo A.
Tao.

Comprehensive protein-protein interaction network analysis can help reveal protein
functions in a system-wide manner. A reliable knowledgebase of interaction networks is
not only important for selecting the candidates for drug therapies, but also for evaluating
the disease risk. In current interaction databases, 322579 interactions comprised of 56460
proteins have been reported (statistical analysis from APID: Agile Protein Interaction
DataAnalyzer; http://bioinfow.dep.usal.es/apid/index.htm). The huge datasets are
contributed mainly by yeast -two -hybrid (Y2H) screening and affinity-purification
followed by mass spectrometry (AP-MS). High false positive rates and failing to cover
certain interaction categories are the limitations of these two methods. Here, we
developed two proteomic strategies to address the limitations. First, we attempt to expand
the dynamic of protein abundance in peptides mixtures by identifying phosphorylated
peptides. The phosphorylation is a ubiquitous post-translation modification which is
involved in regulating the signaling pathway and protein-protein interaction. The step of
phosphopeptide enrichment after immunoprecipitation was employed as the second
purification to reduce the complexity of the samples. With this approach, the sample
complexity was significantly reduced because most of the unmodified peptides were
removed after the phosphopeptide enrichment. In this simplified sample, the number of
many high abundant proteins and peptides identified, such as ribosomal proteins, was
significantly reduced, resulting in improved identification of Plk1 interacting proteins.
We also applied this approach to the PRMT5 network, in which few phosphorylation

xv
events have been reported. In the PRMT5 complex, we identified multiple
phosphoproteins that were not identified in conventional AP-MS, which provided us with
complementary candidates list for follow-up investigation.
For the second strategy, we developed a trifunctional chemical reagent to study the
virus-host interactome. The reagent contains a maleimide group for labeling virus surface
proteins, a biotin tag for capturing the virus particle, and a TAMRA fluorescence
molecule in the first generation reagent for method development. The maleimide group
targets the free thiols on Sindbis virus surface proteins is the critical step to process the
virus modification by the trifunctional reagent. In this study, we successfully captured the
labeled-virus by streptavidin agarose beads from the infected cells, and several identified
host proteins were known to involve in the virus infection pathways which means the
labeled-viruses still maintain the pathogenic property. The method will further replace the
TAMRA fluorescent beacon to a UV-activated photocrosslinker for “fixing” the virus
binding partners after several harsh wash conditions to remove the non-specific binding
protein. We expect the second generation reagent should result in more accurate
identification of host proteins involved in virus infection.
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CHAPTER 1. THE OVERVIEW OF PROTEIN-PROTEIN INTERACTOME

1.1 Interactome
The term of “interactome” was originally coined by Bernard Jacq in 1999 [1].
Interactome usually means the physical interaction between two proteins, but it can also
be considered as indirect interactions among genes. Unlike the signaling cascades,
interacome represents systematically interlinked networks in cells. The importance of
mapping an interaction network includes the identification of the best candidates for
disease therapy development and evaluation of the disease risk. In this decade, many
online interactome databases have become available, and the accumulation of
information is at an increasing pace. The statistical analysis from BioGRID
(http://wiki.thebiogrid.org/doku.php/statistics) indicates that the knowledgebase of
non-redundant physical interactions in all organisms have increased from 88028 links
comprised of 22691 proteins in 2006 to 346181 links comprised of 53603 proteins
currently. The major contribution to the data comes from Homo sapien and
Saccharomyces cerevisiae interactome studies, which contribute 267427 and 85631
non-redundant interactions from 173915 and 6631 proteins, respectively. However,
multiple databases aim to systematically collect the entire set of interactions from
different organisms, but they do not put sufficient effort in filtering out the unreliable
results. The data from independent publications have little overlap to determine which
interactions are correct [2]. The low overlap of datasets is caused by either transient
interactions or ones that occur only under specific stimulation conditions or subcellular
localization. The methods and experimental conditions can also influence the
identification of interacting proteins. Several studies have focused on the quality
improvement of interactome analysis by either building up a scoring database to filter the
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interactions from different interactome databases [3, 4], or by combining the 3D structure
and the binary interaction datasets to visualize the interaction interface [5]. As the simple
accumulation of interaction numbers is no longer with the aim of most researchers.
Instead, a high-quality examination of the interactome network is becoming more
important for the systematic protein-protein interaction study.
1.2 Methods for interactome study
There are two main approaches for detecting protein interactions: The “binary
approach” means the analysis of direct physical interaction between protein pairs. The
other method is “complex approach”, which examines the interactions among groups of
proteins. The yeast-two-hybrid system (Y2H) is the most frequently used binary approach.
It is based on coupling of the bait and prey proteins to the DNA binding and activation
domains of eukaryotic transcriptional activator, respectively. If the two proteins interact,
the transcriptional activator is reconstituted and turns on the reporter gene expression [6].
Although the Y2H provides large-scale screening for binary interactions studies, the
interactions themselves are not under the physiological environment. A positive
interaction in Y2H system does not necessarily represent that the interaction will occur in
cells or whether the interaction has biological functions. Fluorescence Resonance Energy
Transfer (FRET) and Bimolecular Fluorescence Complementation (BiFC) are the
fluorescence-based methods for binary interaction studies in living cells [7, 8]. However,
these two methods are usually used to validate the relation between specific protein
candidates, not as a discovery tool.
The main method of “complex approach” is affinity purification (AP) followed by
mass spectrometry (MS). The AP-MS strategy detects protein-protein interactions by
using antibodies targeting the endogenous bait protein or epitope-tagged targets. The
general procedure of AP-MS includes the immobilization of a ligand (antibody) to a solid
phase (e.g. agarose or magnetic beads), and to capture the target protein and its
interacting partners. The co-purified complex can be analyzed by mass spectrometry
analysis [9]. Since the recent advances in instrumentation have led to high sensitivity and
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faster duty cycles of mass spectrometry, the AP-MS has been gaining momentum over
the past decade as a major tool for protein-protein interaction studies. However, the high
false positive rate from background contaminants is the major problem of AP-MS
strategy. The phenomenon discussed in more detail in the section 1.3.
1.3 The coverage, accuracy and limitations of interactome
As discussed in section 1.1, building up high quality interaction datasets is the main
aim for current interactome studies. The quality of interaction data needs to be validated
by both coverage and accuracy [10]. The statistical analysis of data from APID (Agile
Protein Interaction DataAnalyzer; http://bioinfow.dep.usal.es/apid/index.htm) shows that
there is a very small overlap between the total 80032 human protein-protein interactions
from 6 primary interactome databases (IntAct, HPRD, BioGRID, BIND, MINT and DIP)
[11]. The low coverage by datasets is likely due to individual experimental method for
detecting interactions that have not reached its full potential. For example, some of the
transmembrane transporters and receptors are not easily identified in affinity-purified
complexes because these types of proteins need to be purified by specialized procedures.
In Saccharomyces cerevisiae, more than 30,000 potential interactions among ~6,000
proteins have been estimated [12], but already more than 100,000 binary interactions
between yeast proteins are currently listed in the databases (statistics from APID: Agile
Protein Interaction DataAnalyzer; http://bioinfow.dep.usal.es/apid/index.htm). The
observation indicates that many of the experimental interactions in these datasets are
probably false positives. Low accuracy can be addressed by using different methods to
get complementary data because each detection method has its specific weaknesses. For
instance, the original Y2H system is used to study the interaction of particular protein
pairs, but this method cannot be used for the post-translational modifications-based or
cofactor-based interactions [13]. Not only the potential for such false negative results, but
also for the false positive data by auto-activating transcription of some bait proteins are
the disadvantages of Y2H system [14]. The high – throughput AP-MS contributes the
majority of interaction datasets in this decade. AP-MS can detect complexes in

4

physiological environment, but a number of drawbacks influence the accuracy of this
method. First, the high false positive rate caused by high abundance of background
proteins is the major limitation. The concentration of proteins in human can be dynamic
[15, 16], and after trypsin digestion, high abundant proteins produce very complicated
peptide mixtures. Moreover, some exogenous proteins from careless sample preparation,
such as keratins, are also considered as abundant contaminants. Current mass
spectrometry dynamic range of detection is between 1,000 -10,000 [17]. Highly abundant
proteins dominate the redundant identifications while the low abundance proteins are
inadvertently excluded from the results. Second, some transient or loosely-associated
interaction partners may be lost during the purification and produce false negative results.
Third, some of the interactions may not be detectable under the tested conditions, thus
some synchronization at a specific cell cycle stage or ligand stimulation experiments are
needed. Lastly, a tag on the baits proteins may interfere with the complex formation and
introduce bias during detection.
In this study, we developed new strategies to address the limitations of AP-MS by
using phosphopeptides identification to increase the sensitivity to detect low abundant
proteins, and chemical modification of Sindbis virus surface proteins to study specific
virus-host interactions at the virus early entry stage.
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CHAPTER 2. A NEW STRATEGY TO REVEAL PROTEIN CANDIDATES IN
PROTEIN-PROTEIN INTERACTOMES VIA PHOSPHOPEPTIDE
IDENTIFICATION

2.1 Introduction
2.1.1 The post-translational modifications
The covalent post-translational modification (PTM) on proteins generates diversity
in eukaryotic proteome. The reversible process by specific enzyme-substrate mechanism
alters the protein properties by adding chemical groups to the side chain of residues. The
modified proteins change their properties to response the cellular messages, and then the
destiny of these proteins are led to different ways. Due to the improvement of detection
methods, there are more than 200 PTMs have been found [1] and the statistics of major
PTMs in PhosphositePlus
(http://www.phosphosite.org/homeAction.do) is shown in Figure 2.1A. Some of the
modifications change the protein structure for protein maturation and proper folding, such
as glycosylation and disulfide bond. Acetylation and methylation are known in regulating
the gene expression and histone-DNA or protein-protein interactions [2, 3]. Some
proteins are modified by the covalent attachment of another protein, such as
ubiquitination. The wide-spread phosphorylation is more highly transient and dynamic in
response to extracellular and intracellular signaling. Furthermore, different PTMs can
cooperate in cellular response or compete against others on the same residue to regulate
the function of modified proteins. The crosstalk of PTMs contributes the complexity of
cellular microenvironment [4]. Thus, identification of proteins with PTMs is a potential
way to reveal more interacting candidates in protein interactomes.
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2.1.2 Phosphorylation and protein-protein interaction
Phosphorylation is one of the most wide-spread and early descripted modifications
in eukaryotic proteins [5, 6]. In human proteome, there are 74% of proteins reported to be
phosphorylated at particular moment (Figure 2.1B; statistics from UniProt and
PhosphoSitePlus® ).

Reversible

phosphorylation

is

regulated

by

kinases

and

phosphatases. In eukaryotes, 1.5-2% of protein encoding genes are the protein kinase
families [7]. The protein kinase introduces a phosphoryl group on residues such as serine,
threonine, and tyrosine, and adds negative charges at the physiological pH to disturb the
protein conformation. The structure alternation affects the protein-protein interaction and
the enzyme activity [8]. The major role of the phosphorylation in protein-protein
interaction is to create docking sites for proteins binding [9]. For example, polo-like
kinase 1 (Plk1) is inactivated by the intramolecular interaction between polo-box domain
and kinase domain. The substrate of Plk1 is prior phosphorylated by a priming kinase (e.g.
Cdk1), and then binds to the polo-box domain to release Plk1 auto-inhibition. The relief
of auto-inhibition results in Plk1 activity stimulation and phosphorylates downstream
substrates in the signaling pathway [10, 11].
Due to the ubiquitous property and the roles in protein-protein interaction,
phosphorylation becomes a potential aspect for interactome study. In addition, methods
for phosphopeptide enrichment are relatively specific nowadays, and we can routinely
analyze the phosphopeptides by mass spectrometry. Without the phosphopeptide
enrichment, low occurrence and the negative charge of phosphoryl group make the
peptides difficult to be detected among all non-phosphorylated peptides [12]. The
phosphopeptide enrichment facilitates the phosphopeptides identification in mass
spectrometry

by

removing

many

non-phosphopeptides.

Concurrently,

only

phosphopeptides are isolated from each protein leading to significantly reducing the
complexity of the immunoprecipitation sample. Many phosphorylated proteins are
potentially low abundant, and they can be easily concealed in high background of
abundant proteins, such as ribosomal proteins, cytoskeleton proteins and contaminating
keratins. We reason that the coverage and the sensitivity to identify potential candidates
can be increased after removing the unmodified peptides. Thus, my hypothesis is that the
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ubiquitous phosphorylation can be used to differentiate phosphorylated peptides from
unmodified peptides, to simplify the sample complexity for mass spectrometry analysis,
and to identify complementary interacting candidates in phosphopeptides enriched
sample.
2.1.3 Models in this study
Here, we studied the polo-like kinase 1 (Plk1) and protein arginine
methyltransferase 5 (PRMT5) interaction network. Plk1 network is known to involve in
many phosphorylation regulation events. As a kinase, Plk1 itself is not only activated by
other kinases, but also regulates downstream substrates by phosphorylation. The highly
phosphorylation network leads Plk1 to an ideal positive model for us to test our
hypothesis. To enrich the phosphopeptides, we used the soluble polymer-based metal ion
affinity capture (PolyMAC) [13] with high selectivity and sensitivity in this study. The
experimental design is shown in Figure 2.2. Briefly, the protein complex
immunoprecipitation was achieved with affinity tag and then subjected to different
procedures. In one procedure, the purified protein complex was directly analyzed by
LC-MS/MS (conventional IP-MS), but in another procedure, digested peptides was
treated with PolyMAC before LC-MS/MS analysis. The mass spectrometry results were
compared using known interaction partners and typical highly abundant contaminants
identified in each strategy.
To generalize the strategy, we also applied the strategy to the PRMT5 protein
complex in which few phosphorylation studies have been reported. We hypothesize that
the wide-spread phosphorylation gives us a high chance to discover novel interacting
candidates of PRMT5 through the identification of phosphorylated peptides. Those
candidates could be a transient interaction partner or a low abundant protein which are
masked by highly abundant proteins in the complex. The purpose of the method in this
type of model is to reveal complementary interacting candidates to those identified in a
conventional IP strategy.
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2.2 Materials and Methods
2.2.1 Cell culture and plasmid transfection
HEK293T cells were grown in DMEM with 10% fetal bovine serum and antibiotics
at 37°C and 5% CO2. The X-tremeGENE® 9 DNA transfection reagent (Roche
Diagnostics) was used for transiently transfecting wild-type Plk1-FLAG plasmid (gift
from Xiaoqi Liu’s lab) to cells. After 24 hours transfection, the cells were synchronized
to G2/M phase by 1x Nocodazole. LnCap cells were grown in RPMI with 10% fetal
bovine serum, sodium pyruvate and antibiotics at 37°C and 5% CO2. The Lipofectamine
2000 transfection reagent (Life Technologies) was used for transiently transfecting
myc-PRMT5 plasmid (gift from Chang-Deng Hu’s lab) to cells.
2.2.2 Cell extracts
Transfected cells were harvested by trypsin and washed with sterile PBS. Cell pellet
was resuspended in lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP40]
supplemented with 1x protease inhibitor (Tablet from Roche), 1x phosphatase inhibitor
cocktail (Sigma), 1 mM sodium orthovanadate, and 10 mM sodium floride. Cells were
lysed by probe sonication on ice twice with a 20 second pulse and 10 second interval.
The supernatant containing soluble proteins was collected after centrifugation at 14000
rpm for 10 min. The protein concentration was estimated by using BCA protein assay
(Pierce Biotechnology, Inc.).
2.2.3 Immunoprecipitation
wt-Plk1-FLAG cell lysate was immunoprecipitated with Anti-FLAG® M2 Magnetic
Beads (Sigma), incubated at 4°C on rotator for 4 hours, and further washed with 20x bed
volume of lysis buffer. The complex was eluted by 100 mM Triethylamine (TEA, pH
11.6) or 1% Trifluoroacetic acid. The elutions were dried in a SpeedVac and store at
-80°C for further use.
Myc-PRMT5 cell lysate was overnight incubated with 250:1 (v/v) mouse
myc-tag mAb (Cell Signaling). Protein G agarose beads (Genescript) were added, and
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incubated at 4°C on rotator for 1 hour, further washed with 20x bed volume of lysis
buffer. The complex was eluted by 100 mM Triethylamine (TEA, pH11.6). The elution
was dried in a SpeedVac and store at -80°C for further use.
2.2.4 Reduction, alkylation, trypsin digestion and Nu-Tip® C18 desalting
Alpha-casein was added into the elution for phosphopeptides internal control (lysate:
casein = 10000: 1 w/w). The eluted complex was reduced in 50 mM ammonium
bicarbonate containing 5 mM dithiothreitol for 30 min at 50 °C. The proteins were further
alkylated in 15 mM iodoacetamide for 1 hour in the dark at room temperature and
digested with 0.5 μg proteomics grade trypsin (Sigma) in a total volume of 300 μl
solution containing 50 mM ammonium bicarbonate (pH 8.3) at 37℃ overnight. The
tryptic sample solution was acidified by Trifluoroacetic acid (TFA) to pH ~3. The
Nu-Tip® C18 (Glygen Corp.) were prewetted by pipetting three times with 100%
Acetonitrile (ACN). The tips were equilibrated by pipetting ten times with 0.1% TFA.
The peptides were bound to Nu-Tip by fully pipetting to a dead stop and aspirating
sample 20 cycles, and then washed tips with 0.1% TFA for 15 cycles. Fifty microliters of
0.1%TFA/80% ACN were aspirated into a new sterile centrifuge tubes and pipetted 20
times to elute peptides. The desalting peptides were dried in a SpeedVac.
2.2.5 PolyMAC phosphopeptide enrichment
Tryptic peptides were split into two aliquots. One of the aliquots was dried in a
SpeedVac, and further resuspended by loading buffer (100 mM glycolic acid, 1%
trifluoroacetic acid, 50% acetonitrile). The peptide mixture was incubated with the
PolyMAC and shake vigorously for 5 minutes at ~900 rpm. The capturing buffer (300
mM HEPES, pH 7.7) was added to the mixture to adjust the final pH above 6.3 before
transferring the solution into the magnetic capture beads. The mixture was gently agitated
for 10 minutes at ~900 rpm. The magnetic beads were washed once with loading buffer
and twice with washing buffer (100 mM acetic acid, 1% trifluoroacetic acid, 80%
acetonitrile). The phosphopeptides were eluted by incubating the magnetic beads twice
with 400 mM ammonium hydroxide solution containing 30% acetonenitrile for 5 min.
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The elution was collected and dried in a SpeedVac. The other aliquot of peptides were
purified by Nu-Tip® C18 (Glygen Corp.).
2.2.6 Western Blotting
The eluted proteins and input (total lysate) were separated by SDS-PAGE and
transferred onto PVDF membranes. Membrane was incubated in blocking buffer (10%
BSA in TBS with 0.05% Tween-20) for 1 h at room temperature and then incubated in
blocking buffer containing the 1:1000 dilution of rabblt anti-FLAG antibody (Cell
Signaling Technologies) or mouse myc-tag mAb (Cell Signaling Technologies) at 4°C
overnight. The membranes were then washed three times in TBS with 0.05% Tween-20
for 5min. The membranes were further incubated with horseradish peroxidase-conjugated
anti-rabbit or anti-mouse IgG antibodies (Cell signaling Technologies) for 1 hour at room
temperature.

After

several

washes,

the

blots

were

developed

with

HyGlo

chemiluminescence reagent (Denville scientific, Metuchen, NJ).
2.2.7 Mass spectrometry
The resulting peptides were resuspended in a solution containing 0.25% formic acid
(v/v) and analyzed using an Easy-nLC1000 (Thermo Scientific, San Jose, CA) coupled to
a hybrid mass spectrometer (LTQ-Orbitrap-Velos; Thermo Scientific, San Jose, CA). The
peptides were applied to an analytical column (75 μm x 30 cm, 2.2μm,
ProntoPEARL-120-2.2-C18AQ beads (BISCHOFF chromatography) at ~200 nl/min, and
eluted using a gradient that ran from 5 to 30% of acetonitrile (0.1% formic acid) over 60
minutes. The LTQ-Orbitrap-Velos MS was operated in a data-dependent mode to switch
between MS and MS2 acquisitions. The MS survey scans were acquired over a full m/z
range of 300-2000 by the detector. The 20 most intense precursor ions were sequentially
isolated and subjected to collision induced dissociation (CID) in the linear ion trap. The
general mass spectrometric conditions were: ESI voltage - 2.8 kV; transfer capillary
temperature - 200 °C; and normalized collision energy - 35%.
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2.2.8 Computational analysis of mass spectra
The Excalibur MS raw files were searched against a human database using
SEQUEST algorithm on Proteome Discoverer (version 1.3, Thermo Fisher). The search
parameters included a peptide mass tolerance of 10 ppm and the MS/MS tolerance of 0.8
Da. In the residues modification, the variable modifications were set to +15.9949Da for
the potential oxidation of methionine and to +79.996 Da on serine, threonine, or tyrosine
for the identification of phosphorylation. The static modification of cysteine residues of
+57.0214Da was set due to the alkylation by iodoacetamide. Searches were performed
with full tryptic digestion and allowed a maximum of two missed cleavages on the
peptides. False discovery rates (FDR) were set to 1% for each analysis. Phosphorylation
site localization from CID spectra was determined by PhosphoRS on Proteome
Discoverer 1.3.
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2.3 Results
2.3.1 PLK1 interaction complex analysis: Analysis of Plk1-FLAG expression in
293T cells and the immunoprecipitation with anti-FLAG magnetic beads
Human Plk1 is a cell cycle regulating kinase and plays a key role in spindle
assembly, centrosome maturation, and the mitosis entry and exit progression with many
interacting proteins [11, 14]. The expression level of Plk1 reaches its peak value in
mitotic stage [15]. Here, 293T cells with over-expressed Plk1-FLAG were synchronized
at mitosis with Nocodazole treatment. Plk1 interacting complex was immunoprecipitated
by anti-FLAG magnetic beads. The efficient elution condition has been tested and shown
in Figure 2.3. Both 100mM TEA and 1% TFA can efficiently elute the bait Plk1-FLAG
from anti-FLAG magnetic beads. Thus, the optimum elution was performed by the
combination of TEA and TFA. The Western blot results of Plk1 protein expression and
elution are shown in Figure 2.4. The fusion protein bands are located at the predicted
~70KDa.
2.3.2 MS analysis of Plk1-FLAG complexes
In the Plk1-FLAG immunoprecipitation experiments, a total of 543 proteins (2359
peptides) and 258 proteins (598peptides) against human IPI database were identified
from conventional IP and IP-PolyMAC, respectively (Figure 2.5A). For the internal
control of alpha-casein, we identified 15 unique peptides with 62.15% and 25.68%
sequence coverage from alpha-S1-casein and alpha-S2-casein in IP-only, respectively.
There were only 3 unique phosphorylation sites identified in IP-only. Ten unique
peptides with 24.77% of sequence coverage in alpha-casein S1 and 13.96% of sequence
coverage in alpha-casein S2 were identified after PolyMAC enrichment. Although the
coverage of identified alpha-casein sequence was reduced, the ratio of identified
phosphopeptides to total peptides was increased from 33.3% in IP-only to 94% in
IP-PolyMAC which means the PolyMAC enrichment is efficient.
After the removal of protein identified in the negative control, there were 11 and 14
known Plk1 interacting proteins identified by conventional IP-MS and IP-PolyMAC-MS,
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respectively. In these 17 identified Plk1 interaction proteins, 8 proteins (HSP90, ERCC6L,
P53BP1, GWL, MCM2, SLX4, RanGAP1, WEE1) were listed in both of the two
strategies, 3 proteins (14-3-3, Vimentin, MCM7) were unique in conventional IP-MS data,
and 6 proteins (CDK1, FOXO1, FOXM1, PRC1, BUB1β, MLF1IP) were only identified
in IP-PolyMAC (Figure 2.5A and Table 2.1). None of the known interaction proteins
were identified in negative controls (Figure 2.5B and C).
2.3.3 Data analysis of the Plk1 interacting proteins and the abundant non-specific
proteins
At the protein level, the identified protein number was reduced ~53% from 543
proteins in IP-only to 258 proteins in IP-PolyMAC (Figure 2.6A). However, the ratio of
known Plk1 interactors to total identified proteins in IP-PolyMAC (5.4%) was higher
than IP-only (2.0%) (Figure 2.6B). At the peptide level, PolyMAC can reduce ~75% of
peptides (from 2359 peptides in IP-only to 598 peptides in IP-PolyMAC) (Figure 2.6A),
but the ratio of peptides from known Plk1 interactors was increased from 3.4% in IP-only
to 8.5% in IP-PolyMAC (Figure 2.6B).
In proteomics study, the high abundant proteins such as ribosomal proteins, keratins
and heat shock proteins are commonly identified in the immunoprecipitation “black list”.
Here we identified fewer keratins, heat shock proteins and ribosomal proteins in
IP-PolyMAC than IP-only, especially the number of ribosomal proteins were reduced
~82.5% (Figure 2.7A). The peptides from these proteins were significantly reduced after
PolyMAC treatment (Figure 2.7B).
2.3.4 PRMT5 interaction complex analysis: Analysis of myc-PRMT5 expression in
LnCap cells
The function of Protein arginine methyltransferase 5 (PRMT5) is to modify
chromatin proteins and non-chromatin proteins in several cellular progressions. PRMT5
forms a complex termed the “methylosome” with its cofactor WD repeat protein
(MEP50/WDR77/p44) and different transcriptional regulators [16]. The methylation of
H2A, H4 and H3 [17-19] at specific arginine residues is implicated in gene silencing [20].
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PRMT5 plays an important role in tumorigenesis and the overexpression of PRMT5
facilitates tumor growth by repressing tumor suppression genes [20-22].
The function of PRMT5 methylation is also involved in cell signaling and
transcriptional modification. The methylation of EGFR by PRMT5 leads to EGFR
phosphorylation at tyrosine1197, which then affects ERK signaling and cellular
proliferation [23]. The mutant JAK2 in myeloproliferative disease has been reported to
disrupt the interaction between PRMT5 and its cofactor MEP50 by JAK2V617F-mediated
PRMT5 phosphorylation [24]. PRMT5 associates with MEP50 and pICln, and catalyzes
the methylation of Sm proteins to assembly the small nuclear ribonucleoprotein (SnRNP)
in spliceosome for splicing the cellular pre-mRNA [25].
Myc-PRMT5 was overexpressed in LnCap prostate cancer cell line and the
transfection was examined by Western blot with mouse anti-myc antibody and rabbit
anti-PRMT5 antibody (Figure 2.8). Non-transfected LnCap cells were used as a negative
control. Myc-PRMT5 was detected at MW ~75KDa in the blot with anti-myc antibody.
Endogenous PRMT5 has lower MW than myc-PRMT5 in the blot with anti-PRMT5
antibody. Equivalent protein loading on the gel was confirmed by the level of GAPDH.
2.3.5 Western blot analysis of immunoprecipitation with anti-myc antibody
PRMT5 complex was immunoprecipitated with anti-myc antibody and captured on
the protein G agarose beads. The efficient elution condition has been tested by a series of
elution buffers. As demonstrated in Figure 2.9, the complex was eluted efficiently by
100mM TEA (pH11.6), and additional myc-PRMT5 was not detected in subsequent
elutions done by incubating with 1% TFA or by boiling in SDS sample buffer. Thus, the
optimum elution was performed by TEA. The western blot result of myc-PRMT5
immunoprecipitation with anti-myc antibody is shown in Figure 2.10. The myc-PRMT5
was clearly detected in immunoprecipitation of transfected LnCap cells but not in
negative control. Equivalent total lysates for immunoprecipitation were confirmed by the
level of GAPDH.
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2.3.6 MS analysis of PRMT5 complexes
In myc-PRMT5 immunoprecipitation experiment, after the removal of protein
identified in the negative control, there were 105 proteins identified by conventional
IP-MS and 28 proteins by IP-PolyMAC. Several PRMT5 interacting proteins including
MEP50, pICln, smD1, smD2, smD3, SNRPE, HSP90 [26], NFkB [27] and SERPB1[28]
were identified in the IP sample indicating overall immunoprecipitation was successful
(Figure 2.11). As expected due to low phosphorylation events in the complex, PolyMAC
treatment significantly reduced identified proteins and the unique protein list
complements to conventional IP strategy. The overlapped proteins which identified by
both strategies were the bait PRMT5 and its regulating partner pICln. A total of 26
potentially novel candidates were identified after PolyMAC treatment. With
IP-PolyMAC strategy, PRMT5, pICln and HSP90 known to be involved in PRMT5
network were identified with phosphorylation sites at ser15 and ser16 in PRMT5, ser102
in pICln and ser177 in HSP90B2. The phosphorylation sites in pICln and HSP90B2 were
previously reported by unrelated large-scale phosphoproteome screening [29-31], but
their functions and mechanisms have not yet been reported. Reports of PRMT5
phosphorylation are extremely limited and the two phosphorylation sites identified in
PRMT5 in our study were novel.
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2.4 Discussion
2.4.1 The identified interacting partners coordinate mitotic progression with Plk1
The 14 Plk1 interacting partners in IP-PolyMAC were known to be involved in
coordinating mitotic progression with Plk1. The proteins involved in kinetochore
localization are RanGAP1 [32] and BUB1β [33]. PRC1 [34] which is a protein regulated
by Plk1 to prevent the premature of midzone formation before cytokinesis. CDK1 is a
priming kinase in mitosis to phosphorylate several substrates and form a positive
feedback loop to regulate the mitosis stage [35-37]. MLF1IP [38] help the chromosome
segregation, and FOXO1[35, 36], FOXM1 [39] and WEE1 [40] control the entry of
mitosis. MCM2-MCM7 complex coordinates DNA replication with Plk1 [41]. SLX4 [42,
43] and ERCC6L [44] (also named PICH) are involved in DNA repair. HSP90 [45]
regulates the metaphase-anaphase transition, and GWL [46] coordinates the checkpoint
recovery in a Plk1-dependnet manner. In addition, Plk1 has a potential role in inhibiting
the function of P53BP1 in tumorigenesis [47].
The polo-box domain of Plk1 recognizes Ser-[pSer/pThr]-Pro/X motif on polo
kinase substrates [48]. We extracted the significant motifs from the identified peptides of
the 14 known Plk1 interaction proteins in IP-PolyMAC by motif-x program
(http://motif-x.med.harvard.edu/motif-x.html), the motif logo is consistent with a serine
at the -1 position and a strongly selection for proline at the +1 position (Fig 2.12).
2.4.2 PolyMAC treatment provides an efficient way to simplify the affinity
capture-mass spectrometry data for candidate selection
While hundreds of proteins in an immunoprecipitation sample can be detected in a
single mass spectrometry experiment, selecting interesting candidates for validation and
in-depth biological characterization is a daunting task. Abundant proteins usually
dominate the detection and hamper the MS sensitivity and coverage in a typical LC-MS
analysis, which makes it even more difficult to choose interesting candidates for
validation. The IP-PolyMAC distinguishes itself from the conventional IP strategy by the
second purification via phosphopeptide enrichment. We reason that phosphorylation can
be used as a filter to simplify the immunoprecipitation sample, and address the major
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drawback of highly abundant contaminants in conventional IP-MS. Several benefits were
gained by IP-PolyMAC strategy. First, most of the unmodified peptides were removed,
especially the peptides from highly abundant proteins such as ribosomal proteins and
contaminating keratins. The phosphopeptide enrichment step efficiently reduced the high
background of dominating proteins in MS analysis. Second, the number of identified
proteins was significantly reduced after PolyMAC treatment to facilitate researchers to
choose important candidates for follow-up experiments. Third, the enrichment of
phosphopeptides in IP sample yields the modification sites that have potential roles for
future investigation. In summary, suppressing background abundant proteins via
phosphopeptide enrichment, our IP-PolyMAC strategy provided high sensitivity and
specificity of result in Plk1 network.
2.4.3 Summary and future directions in analysis of the Plk1 complex
Protein phosphorylation plays a pivotal role in regulating protein-protein interaction.
Dysfunctional protein-protein interactions lead to several diseases such as human
malignancies. However, current methods for interactome study present multiple
drawbacks that prevent researchers to understand the network and identify important
interacting proteins. In this project, we have illustrated a strategy with tandem
purification steps, including immunoprecipitation and phosphopeptide enrichment for
screening the interacting partners. The addition of the second purification by PolyMAC
significantly reduces the number of abundant proteins and reveals novel proteins in the
complex. These included stathmin, a protein involved in tubulin dynamics; NFkB,
Mre11A, MDC1 and HMGA1, the proteins involved in DNA damage repairing; and
ACAA1, EIF5B and PRKAR2A which are related to metabolism in the Plk1 complex
(Table 2.3). Stathmin is a particularly interesting identification because in
stathmin-depleted cells, recruitment of Plk1 to the centrosome is delayed, and the
activation of Aurora A, which is an upstream kinase of Plk1, is reduced [49]. We
identified two phosphorylation sites at Ser16 and Ser25 on stathmin. Ser16
phosphorylation was known in response to increased intracellular calcium, and Ser25 was
reported to be the target site for the mitogen-activated protein (MAP) kinase family [50].
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Mutation of Ser16 and Ser63 on stathmin abolished Aurora A phosphorylation [49].
While stathmin depletion influences the activities of Plk1 and Aurora A at mitotic entry,
the precise mechanism regulating these enzymes is not yet clear. We hypothesize that the
other eight candidate proteins found in our study may also play essential roles via their
identified phosphorylation sites to regulate cellular functions with Plk1.

2.4.4 IP-PolyMAC strategy provides a complementary approach to reveal potential
candidates in PRMT5 network
The two strategies by conventional IP and IP-PolyMAC provided complementary
protein lists in PRMT5 complex. The overlapping proteins in these two approaches were
the bait PRMT5 and its regulating partner, pICln. With IP-PolyMAC strategy, only 28
proteins were identified after removing the proteins in the negative control. The low
number of identified proteins is as expected, because the PRMT5 complex, which few
phosphorylation events have been reported, is carefully selected as a model system to test
our strategy. We significantly reduced the number of identified proteins from hundreds to
less than 30. The simplified candidate list allows researchers to focus and select
interested proteins for future test. Moreover, the phosphorylation sites that we identified
can also be used for studies of mechanisms on particular phosphorylated residues by
mutagenesis.
2.4.5 Future direction in PRMT5 complex
Beside the Plk1 complex, we have tried to investigate the anaphase –promoting
complex (APC) and the proteasome complex for testing our hypothesis; however, the two
complexes are too stable and well-defined to have better results with IP-PolyMAC
strategy. The PRMT5 complex is a challenge model because more transient interactions
events than above stable complexes in PRMT5 network. The difficulty of testing a
transient interaction model is the random patterns of the identified proteins in each
immunoprecipitation experiment. Because the low number of identified proteins in this
study is the outcome of a single experiment, it is difficult to define the 26 unique
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identified proteins in IP-PolyMAC are all the PRMT5 interacting proteins. We are trying
to complete the biological and technical replications in this model and to get a more
convincible protein list for future investigation. However, in this study, two interesting
candidate proteins in IP-PolyMAC were selected by our collaborator for investigation,
the

mitochondria

uncoupling

proteins

2,

UCP2;

and

the

histone-lysine

N-methyltransferase SETD1B (Table 2.3).
UCP2 is a mitochondrial transporter protein which known to be involved in
regulation of energy expenditure, obesity [51] and aging [52]. SETD1B is a histone
methyltransferase which associates with DNA methyltransferases DNMT3A to promote
the silence of tumor suppressor gene [53]. The interaction evidence of UPC2, SETD1B
and PRMT5 has not yet been reported. In this study, several novel phosphorylation sites
in UCP2 and SETD1B were identified by IP-PolyMAC, which may reveal important
functions of the PRMT5 complex in the regulation of energy expenditure or the
modification of chromatin.

22
2.5 Reference

1.

Mann, M. and O.N. Jensen, Proteomic analysis of post-translational
modifications. Nature biotechnology, 2003. 21(3): p. 255-61.

2.

Strahl, B.D. and C.D. Allis, The language of covalent histone modifications.
Nature, 2000. 403(6765): p. 41-5.

3.

Kouzarides, T., Chromatin modifications and their function. Cell, 2007. 128(4): p.
693-705.

4.

Simonsson, M., et al., The balance between acetylation and deacetylation
controls Smad7 stability. The Journal of biological chemistry, 2005. 280(23): p.
21797-803.

5.

Fischer, E.H. and E.G. Krebs, Conversion of phosphorylase b to phosphorylase a
in muscle extracts. The Journal of biological chemistry, 1955. 216(1): p. 121-32.

6.

Walsh,

D.A.,

J.P.

Perkins,

and

E.G.

Krebs,

An

adenosine

3',5'-monophosphate-dependant protein kinase from rabbit skeletal muscle. The
Journal of biological chemistry, 1968. 243(13): p. 3763-5.
7.

Manning, G., et al., Evolution of protein kinase signaling from yeast to man.
Trends in biochemical sciences, 2002. 27(10): p. 514-20.

8.

Johnson, L.N. and R.J. Lewis, Structural basis for control by phosphorylation.
Chemical reviews, 2001. 101(8): p. 2209-42.

9.

Deribe, Y.L., T. Pawson, and I. Dikic, Post-translational modifications in signal
integration. Nature structural & molecular biology, 2010. 17(6): p. 666-72.

10.

Bruinsma, W., et al., Bora and Aurora-A continue to activate Plk1 in mitosis.
Journal of cell science, 2014. 127(Pt 4): p. 801-11.

11.

Barr, F.A., H.H. Sillje, and E.A. Nigg, Polo-like kinases and the orchestration of
cell division. Nature reviews. Molecular cell biology, 2004. 5(6): p. 429-40.

12.

Steen, H., et al., Phosphorylation analysis by mass spectrometry: myths, facts,
and the consequences for qualitative and quantitative measurements. Molecular
& cellular proteomics : MCP, 2006. 5(1): p. 172-81.

23
13.

Iliuk,

A.B.,

et

al.,

In-depth

analyses

of

kinase-dependent

tyrosine

phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol
Cell Proteomics, 2010. 9(10): p. 2162-72.
14.

Petronczki, M., P. Lenart, and J.M. Peters, Polo on the Rise-from Mitotic Entry to
Cytokinesis with Plk1. Developmental cell, 2008. 14(5): p. 646-59.

15.

Golsteyn, R.M., et al., Cell cycle regulation of the activity and subcellular
localization of Plk1, a human protein kinase implicated in mitotic spindle function.
The Journal of cell biology, 1995. 129(6): p. 1617-28.

16.

Friesen, W.J., et al., A novel WD repeat protein component of the methylosome
binds Sm proteins. The Journal of biological chemistry, 2002. 277(10): p. 8243-7.

17.

Pollack, B.P., et al., The human homologue of the yeast proteins Skb1 and Hsl7p
interacts with Jak kinases and contains protein methyltransferase activity. The
Journal of biological chemistry, 1999. 274(44): p. 31531-42.

18.

Lacroix, M., et al., The histone-binding protein COPR5 is required for nuclear
functions of the protein arginine methyltransferase PRMT5. EMBO reports, 2008.
9(5): p. 452-8.

19.

Fabbrizio, E., et al., Negative regulation of transcription by the type II arginine
methyltransferase PRMT5. EMBO reports, 2002. 3(7): p. 641-5.

20.

Karkhanis, V., et al., Versatility of PRMT5-induced methylation in growth control
and development. Trends in biochemical sciences, 2011. 36(12): p. 633-41.

21.

Wang, L., S. Pal, and S. Sif, Protein arginine methyltransferase 5 suppresses the
transcription of the RB family of tumor suppressors in leukemia and lymphoma
cells. Molecular and cellular biology, 2008. 28(20): p. 6262-77.

22.

Shilo, K., et al., Cellular localization of protein arginine methyltransferase-5
correlates with grade of lung tumors. Diagnostic pathology, 2013. 8: p. 201.

23.

Hsu, J.M., et al., Crosstalk between Arg 1175 methylation and Tyr 1173
phosphorylation negatively modulates EGFR-mediated ERK activation. Nature
cell biology, 2011. 13(2): p. 174-81.

24
24.

Liu, F., et al., JAK2V617F-mediated phosphorylation of PRMT5 downregulates
its methyltransferase activity and promotes myeloproliferation. Cancer Cell, 2011.
19(2): p. 283-94.

25.

Meister, G., et al., Methylation of Sm proteins by a complex containing PRMT5
and the putative U snRNP assembly factor pICln. Current biology : CB, 2001.
11(24): p. 1990-4.

26.

Trepel, J., et al., Targeting the dynamic HSP90 complex in cancer. Nature reviews.
Cancer, 2010. 10(8): p. 537-49.

27.

Tanaka, H., et al., PRMT5, a novel TRAIL receptor-binding protein, inhibits
TRAIL-induced apoptosis via nuclear factor-kappaB activation. Molecular cancer
research : MCR, 2009. 7(4): p. 557-69.

28.

Cheng, D., et al., The arginine methyltransferase CARM1 regulates the coupling
of transcription and mRNA processing. Molecular cell, 2007. 25(1): p. 71-83.

29.

Daub,

H.,

et

al.,

Kinase-selective

enrichment

enables

quantitative

phosphoproteomics of the kinome across the cell cycle. Molecular cell, 2008.
31(3): p. 438-48.
30.

Dephoure, N., et al., A quantitative atlas of mitotic phosphorylation. Proceedings
of the National Academy of Sciences of the United States of America, 2008.
105(31): p. 10762-7.

31.

Olsen, J.V., et al., Global, in vivo, and site-specific phosphorylation dynamics in
signaling networks. Cell, 2006. 127(3): p. 635-48.

32.

Hutchins, J.R., et al., Systematic analysis of human protein complexes identifies
chromosome segregation proteins. Science, 2010. 328(5978): p. 593-9.

33.

Qi, W., Z. Tang, and H. Yu, Phosphorylation- and polo-box-dependent binding of
Plk1 to Bub1 is required for the kinetochore localization of Plk1. Molecular
biology of the cell, 2006. 17(8): p. 3705-16.

34.

Hu, C.K., et al., Plk1 negatively regulates PRC1 to prevent premature midzone
formation before cytokinesis. Molecular biology of the cell, 2012. 23(14): p.
2702-11.

25
35.

Kim, A.H. and A. Bonni, Cdk1-FOXO1: a mitotic signal takes center stage in
post-mitotic neurons. Cell Cycle, 2008. 7(24): p. 3819-22.

36.

Yuan, Z., et al., Activation of FOXO1 by Cdk1 in cycling cells and postmitotic
neurons. Science, 2008. 319(5870): p. 1665-8.

37.

Maia, A.R., et al., Cdk1 and Plk1 mediate a CLASP2 phospho-switch that
stabilizes kinetochore-microtubule attachments. J Cell Biol, 2012. 199(2): p.
285-301.

38.

Kang, Y.H., et al., Self-regulated Plk1 recruitment to kinetochores by the
Plk1-PBIP1 interaction is critical for proper chromosome segregation. Mol Cell,
2006. 24(3): p. 409-22.

39.

Fu, Z., et al., Plk1-dependent phosphorylation of FoxM1 regulates a
transcriptional programme required for mitotic progression. Nat Cell Biol, 2008.
10(9): p. 1076-82.

40.

Lindqvist, A., V. Rodriguez-Bravo, and R.H. Medema, The decision to enter
mitosis: feedback and redundancy in the mitotic entry network. The Journal of
cell biology, 2009. 185(2): p. 193-202.

41.

Tsvetkov, L. and D.F. Stern, Interaction of chromatin-associated Plk1 and Mcm7.
J Biol Chem, 2005. 280(12): p. 11943-7.

42.

Svendsen, J.M., et al., Mammalian BTBD12/SLX4 assembles a Holliday junction
resolvase and is required for DNA repair. Cell, 2009. 138(1): p. 63-77.

43.

Svendsen, J.M. and J.W. Harper, GEN1/Yen1 and the SLX4 complex: Solutions to
the problem of Holliday junction resolution. Genes Dev, 2010. 24(6): p. 521-36.

44.

Baumann, C., et al., PICH, a centromere-associated SNF2 family ATPase, is
regulated by Plk1 and required for the spindle checkpoint. Cell, 2007. 128(1): p.
101-14.

45.

de Carcer, G., Heat shock protein 90 regulates the metaphase-anaphase transition
in a polo-like kinase-dependent manner. Cancer Res, 2004. 64(15): p. 5106-12.

46.

Peng, A., L. Wang, and L.A. Fisher, Greatwall and Polo-like kinase 1 coordinate
to promote checkpoint recovery. J Biol Chem, 2011. 286(33): p. 28996-9004.

26
47.

Ando, K., et al., Polo-like kinase 1 (Plk1) inhibits p53 function by physical
interaction and phosphorylation. J Biol Chem, 2004. 279(24): p. 25549-61.

48.

Elia,

A.E.,

L.C.

Cantley,

and

M.B.

Yaffe,

Proteomic

screen

finds

pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science, 2003.
299(5610): p. 1228-31.
49.

Silva, V.C. and L. Cassimeris, Stathmin and microtubules regulate mitotic entry
in HeLa cells by controlling activation of both Aurora kinase A and Plk1.
Molecular biology of the cell, 2013. 24(24): p. 3819-31.

50.

Brattsand, G., et al., Cell-cycle-regulated phosphorylation of oncoprotein 18 on
Ser16, Ser25 and Ser38. European journal of biochemistry / FEBS, 1994. 220(2):
p. 359-68.

51.

Fleury, C., et al., Uncoupling protein-2: a novel gene linked to obesity and
hyperinsulinemia. Nature genetics, 1997. 15(3): p. 269-72.

52.

Andrews, Z.B., Uncoupling protein-2 and the potential link between metabolism
and longevity. Current aging science, 2010. 3(2): p. 102-12.

53.

Li, H., et al., The histone methyltransferase SETDB1 and the DNA
methyltransferase DNMT3A interact directly and localize to promoters silenced
in cancer cells. The Journal of biological chemistry, 2006. 281(28): p. 19489-500.

54.

Huggins, D.J., et al., Computational analysis of phosphopeptide binding to the
polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation.
PLoS Comput Biol, 2010. 6(8).

55.

Yamaguchi, T., et al., Phosphorylation by Cdk1 induces Plk1-mediated vimentin
phosphorylation during mitosis. J Cell Biol, 2005. 171(3): p. 431-6.

56.

Park, J.E., et al., Polo-box domain: a versatile mediator of polo-like kinase
function. Cell Mol Life Sci, 2010. 67(12): p. 1957-70.

27

Figures
(A)

Acetylation
15%

O-Glycosylation
1%
Methylation
Sumoylation
4%
0%

Ubiquitinylation
27%

Serine
phosphorylation
35%

Tyrosine
phosphorylation
8%

Threonine
phosphorylation
10%

Modification Sites
in PhosphoSitePlus®

(B)

Phosphoproteins in human proteome
20232
15064

Total Protein#
Phosphoprotein#

Figure 2.1 Calculations of posttranslational modifications in PhosphoSitePlus® and
the phosphoproteins in human proteome. (A) The percentage of each PTM in
PhosphoSitePlus® database. (B) The human phosphoproteins from Uniprot and
PhosphositePlus® databases are calculated.
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Figure 2.2 Work flow of the experimental design. (Left) In the Plk1 network study,
wt-Plk1-FLAG was overexpressed in HEK 293T cells and the cells were treated with
Nocodazole to arrest in mitosis. Anti-FLAG magnetic beads were used to capture the
Plk1 complex. (Right) In the PRMT5 network study, myc-PRMT5 was overexpressed in
LnCap cells and the PRMT5 complex was captured by anti-myc antibody and protein G
agarose beads. The critical step is the second purification of immunoprecipitated complex
by phosphopeptide enrichment via PolyMAC (IP-PolyMAC). The procedure of
immunoprecipitation and PolyMAC phosphopeptide enrichement are described in detail
in the section of Materials and Methods.
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Figure 2.3 Western blotting analysis of the Plk1-FLAG affinity purification with
different elution conditions. Wt-Plk1-FLAG cell lysate was immunoprecipitated with
Anti-FLAG® M2 magnetic beads (Sigma), further washed with lysis buffer three times
and eluted with 100 mM Triethylamine (TEA), pH 11.6 or 1% Trifluoroacetic acid (TFA).
The loading amount of each sample was 1% of total volume. Plk1-FLAG protein was
detected by Western blot with anti-FLAG antibody. The magnetic beads were boiled by
SDS sample buffer after TEA or TFA elution (SDS re-elution) to examine the elution
efficiencies by TEA and TFA. (-) indicates the negative control which was
non-transfected cells.
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Figure 2.4 Western blotting analysis of the Plk1-FLAG affinity purification. 293T
cells overexpress Plk1-FLAG were synchronized at G2/M phase by Nocodazole,
precipitated with anti-FLAG magnetic beads and visualized by Western blot with mouse
anti-FLAG antibody. The loading amount of each sample is indicated by the percentage
of total volume (Loading V%). The bands of Plk1-FLAG are shown by arrow.
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Figure 2.5 Summary of Plk1 interaction proteins identified by conventional IP and
IP-PolyMAC strategies. (A) Fourteen of 258 identified proteins in IP-PolyMAC were
known Plk1 interacting proteins and six of the 14 proteins (CDK1, FOXO1, FOXM1,
PRC1, BUB1β and MLF1IP) were uniquely identified in IP-PolyMAC. Eleven of 543
identified proteins in IP-PolyMAC were known Plk1 interactors, but only 3 proteins
(14-3-3, Vimentin and MCM7) were unique in IP-Only. Eight known interaction proteins
(HSP90, ERCC6L, P53BP1, GWL, MCM2, SLX4, WEE1 and RANGAP1) were listed in
both of the two strategies. The overlapping proteins with (B) negative control have been
removed for the statistics in (A).
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Figure 2.6 Data analysis of known Plk1 interactors in total number of protein and
peptides. (A) The IP-PolyMAC strategy (Grey bar) reduced the candidate list at both
protein and peptide levels. ~53% and ~75% of total protein and peptides were reduced
after PolyMAC treatment; (B) The ratio of known Plk1 interacting proteins in the
candidates list is higher in IP-PolyMAC (Grey bar) than IP-only (Dark bar).
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Figure 2.7 Comparison of three groups of high abundant proteins, keratin (KRT),
heat shock proteins (HSP) and ribosomal proteins identified by IP-only (Red) and
IP-PolyMAC (Blue) strategies. (A) At the protein level, the protein number of identified
ribosomal proteins was significantly reduced from 40 in IP-only to 7 in IP-PolyMAC.
(B)At the peptide level, the peptide number from keratin, HSP and ribosomal proteins
were reduced by 86.7%, 94.5% and 92.4% after PolyMAC treatment, respectively.
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Figure 2.8 Western blotting analysis of the myc-PRMT5 overexpression in LnCap
cells. Mouse myc-tag antibody was used for detecting the myc-PRMT5, and the rabbit
PRMT5 antibody was used for detecting both myc-PRMT5 and endogenous PRMT5.
GAPDH serves as a loading control.
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Figure 2.9 Western blotting analysis of the myc-PRMT5 affinity purification with
series elution conditions. LnCap cells overexpressing myc-PRMT5 was precipitated
with anti-myc antibody and protein G agarose beads. The bait protein was visualized by
Western blot against mouse anti-myc antibody. The myc-PRMT5 complex was eluted by
a series of buffer -- 100mM TEA, pH11.6 (E1), 1% TFA (E2) and 2.5x LDS sample
buffer (E3). FT: flowthrough. GAPDH serves as a loading control.
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Figure 2.10 Western blotting analysis of the myc-PRMT5 affinity purification. Ten
percent of the total lysate (Input) and 30% of IP elution by SDS sample buffer were
loaded into gel. Blotting was against mouse myc-Tag mAb and rabbit anti-GAPDH
antibody (loading control), respectively. Negative control is non-transfected LnCap cells.
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Figure 2.11 Venn diagram of identified proteins in MS analysis by conventional IP
(IP-only) and IP-PolyMAC strategies. The known PRMT5 interacting proteins are
listed. The number does not include those identified in negative controls. H2A, histone
H2A; H3, histone H3; H4, histone H4; sm D1-D3, small nuclear ribonucleoprotein Sm
D1- D3; SNRPE, small nuclear ribonucleoprotein E; NFkB, nuclear factor NF-kappa-B;
HSP90A, HSP90B and HSP90B2, heat shock protein 90 alpha, beta and beta-2; PRMT5,
protein arginine N-methyltransferase 5; pICln, methylosome subunit pICln.
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Figure 2.12 Motif analysis of the 14 known Plk1 substrate in IP-PolyMAC for
polo-box binding domain specificity: the distribution of amino acid residue is depicted
by Motif-x.
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Tables
Table 2.1 Known Plk1 interacting proteins in IP-only and IP-PolyMAC
Known interacting proteins in IP-PolyMAC
BUB1b
[33]
PRC1
[34]
FOXO1
[35, 36]
CDK1
[35-37]
MLF1IP
[38]
FOXM1
[39]
Known interacting proteins in overlaps
RanGAP1
[32]
WEE1
[40]
MCM2
[41]
SLX4
[42, 43]
ERCC6L
[44]
HSP90
[45]
GWL
[46]
P53BP
[47]
Known interacting proteins in IP-only
Protein name
Reference
MCM7
[41]
14-3-3
[54]
Vimentin
[55, 56]
Abbreviations: BUB1b, mitotic checkpoint serine/threonine-protein kinase BUB1 beta;
PRC1, protein regulator of cytokinesis1; FOXO1, forkhead box protein O1; CDK1,
cyclin-dependent kinase 1; MLF1IP, centromere protein U; FOXM1, forkhead box
protein M1; RanGAP1, ran GTPase-activating protein 1; WEE1, Wee1-like protein
kinase; MCM2, DNA replication licensing factor MCM2; SLX4, structure-specific
endonuclease subunit SLX4; ERCC6L, DNA excision repair protein ERCC-6-like;
HSP90, heat shock protein 90; GWL, serine/threonine-protein kinase greatwall; P53BP,
Tumor suppressor p53-binding protein; MCM7, DNA replication licensing factor
MCM7.
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Table 2.2 PRMT5 interacting candidates identified in IP-PolyMAC
Accession
G3V5W5
H0YDD8
B4DYL6
E9PJF4
B7Z1H6
P55851
B7Z6T4
Q9H1E3
B7Z918
O43474
Q58FF8
B4DG58
E7ER26
P38570
Q9UPS6
Q504Y0

Phosphopeptides
Description
VSSGRDLNCVPEIADT Protein arginine N-methyltransferase 5
LGAVAK
KEESEESDDDMGFGLF 60S acidic ribosomal protein P2
D
ASGQVMALKMNTLSS cDNA FLJ58888, highly similar to dual
NRANMLK
specificity testis-specific protein kinase 2
FEEESKEPVADEEEED Methylosome subunit pICln
SDDDVEPITEFR
GVVPNTRRMVLTLPS cDNA FLJ52121, highly similar to
GAVC
Fructose-bisphosphate aldolase C
YMNSALGQYSSAGHC Mitochondrial uncoupling protein 2
ALTMLQKEGPR
MVPKGATMLVIPPGLS cDNA FLJ56180, highly similar to negative
EEEEALQK
elongation factor E
NSQEDSEDSEDKDVK Nuclear ubiquitous casein and
cyclin-dependent kinase substrate 1
GRPVPMMIPDELAPTY cDNA FLJ61074, highly similar to
SLDTR
Echinoderm microtubule-associated
protein-like 2
QLPSRTTPTLGLEEVL Isoform 3 of Krueppel-like factor 4
SSR
IEDVGSDEEDDSGKDK Putative heat shock protein HSP 90-beta 2
TGSQHGPQNAAAATF cDNA FLJ55967, highly similar to Catenin
QRASYAAGPASNYAD delta-2
PYR
EEFIGKIGISSEENDDNS PR domain zinc finger protein 15
DESADSEPHKYSCK
YHSLPIIIKGSVGGLLV Integrin alpha-E precursor
LIVILVILFK
DGGLSAGCGSGSSSV Histone-lysine N-methyltransferase
TPNSGGTPFSQDTAYS SETD1B
SCR
FLVYISR
Isoform 2 of Zinc transporter ZIP12
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Table 2.2 Continued
Accession
IPI00477734.2
IPI00793191.1
IPI00936437.2
Q14520
Q96GX5
H0YBY6
Q86X95
Q86WV7
E9PN89

Phosphopeptides
TTEDLSFK
MQNLNDSLVSYLDK
TQSADWLRVSVPIGQSP
K
N/A
N/A
N/A
N/A
N/A
N/A

Q6ZNW8
IPI00976333.1
P10636
H0YCA0

N/A
N/A
N/A
N/A

Description
15 kDa protein
14 kDa protein
hypothetical protein LOC100287063
Hyaluronan-binding protein 2
Serine/threonine-protein kinase greatwall
Disks large-associated protein 2 (Fragment)
Corepressor interacting with RBPJ 1
CCDC43 protein
Heat shock cognate 71 kDa protein
(Fragment)
CDNA FLJ26989 fis, clone SLV03395
Novel protein (SAMD)
microtubule-associated protein tau isoform 1
Cullin-5 (Fragment)

Lower case of S, T, and Y = identified phosphorylation sites in this study
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Table 2.3 Plk1 and PRMT5 selected candidates for future investigation

Protein name
Stathmin
NFkB
MRE11A
HMGA
ACAA

PLK1 complex
Site of phosphoprylation
RAsGQAFELILsPR
IGELGAPEVWGLsPK
NYSEVIEVDEsDVEEDIFPTTSK
KLEKEEEEGISQESSEEEQ
KDGTVTAGNASGVADGAGAVIIASEDAVKK

MDC1
PRKAR2A
EIF5B

LLLAEDSEEEVDFLSER
VADAKGDSESEEDEDLEVPVPSR
VEMYSGSDDDDDFNKLPK

FOXO1
Protein name
UPC2

ASLQSGQEGAGDSPGSQFSK
PRMT5 complex
Site of phosphoprylation
YMNSALGQYSSAGHCALTMLQKEGPR

SETD1B

DGGLSAGCGSGSSSVTPNSGGTPFSQDTAYSSCR

S16, S25
S149
S493
S91, S92
T244,
T246,
S251
S168
S78, S80
Y134,
S135,
S137
S261

S251,
S252,
T259
S247,
S253,
S259,
S260

Abbreviations: NFkB, NF-kappa-B-activating protein; MRE11A, isoform 2 of
Double-strand break repair protein MRE11A; HMGA, isoform HMG-Y of High
mobility group protein HMG-I/HMG-Y; EIF5B, eukaryotic translation initiation
factor 5B; MDC1, Mediator of DNA damage checkpoint 1; ACAA,
3-ketoacyl-CoA thiolase, mitochondrial; PRKAR2A, protein kinase,
cAMP-dependent, regulatory, type II, alpha, isoform CRA_b; FOXO1, Forkhead
box protein O1.
Lower case of S, T, and Y = identified phosphorylation sites in this study
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CHAPTER 3. SINDBIS VIRUS - HOST INTERACTOME STUDY VIA
CHEMICAL MODIFICATION

3.1 Introduction
3.1.1 Host-Virus interactome study
Viruses have rapid replication cycle and genomic variants in hosts which cause
serious problems in humans, agriculture and livestock. The properties of rapid mutation
and recombination to adopt the host environment lead to a complex epidemiology.
Currently, several genomics and proteomics approaches are used to study virus-host
interactions, particularly since the rapid accumulation of sequence database.
High-throughput genome-wide RNAi screening has been used for studying the host
factors required for replication of Influenza A virus [1, 2], Dengue virus [3] and human
HIV [4]. The proteomics tools including two-dimensional differential in-gel
electrophoresis (2-D DIGE), MALDI-MS/MS and LC-MS/MS combined with
quantitative methods have been used to reveal the physical interaction between virus and
host cells, and to monitor the dynamic cellular proteome responses during the infection
[5-7]. The above studies have expanded the knowledge of host response to virus infection;
however, the progress of proteomics studies has lagged behind the genomics-wide studies
because of the complexity of the cellular proteome. But using the genome-wide approach,
the mRNA levels cannot fully represent the levels of protein synthesis or the
posttranslational modifications on proteins which are related to the interaction network.
Thus, high- throughput virus-host interactome studies by proteomic approaches still have
a great space for improvement.
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3.1.2 Sindbis virus
Alphaviruses are a group of enveloped viruses which are emerging pathogens that
cause human diseases [8]. The symptoms of pathogenic alphaviruses are fever, rash,
arthritis and encephalitis [9]. Alphaviruses represent a new threat for global infection and
transmission [10], but the host molecules which are involved in the infection process are
still obscure. Sindbis virus is a prototypical member of the genus that has been
engineered for heterologous gene expression [11]. Sindbis virus is important for vaccine
development due to the high-level expression of heterologous protein per cell and the
broad range of hosts from mosquitoes to vertebrates [12]. There are four structural
proteins, E1 (47KDa), E2 (46KDa), 6K and capsid proteins (29KDa), and four
non-structure proteins in Sindbis virus. The 240 copies of E1 and E2 are arranged as
E1-E2 heterodimer which is embedded in a host plasma membrane-derived lipid bilayer,
and the 240 copies of capsid protein with one copy of genomic RNA form the
nucleocapsid core (NC) in the icosahedral symmetry [13]. E2 and E1 are integral
membrane proteins, with E2 functioning as the host receptor interactor [14], and E1 is
required for virus entry by a pH-dependent fusogenic property [15].
Because of the prototypical property and vaccine development application, the
Sindbis virus is the ideal model for us to study the early point of infection by chemical
modification of the surface proteins. We propose to tag the E1 or E2 proteins with a
trifunctional reagent for labeling, capturing, and crosslinking its target, and study the
interaction between virus and host factors at the early entry stage.
3.1.3 Aspect of virology by chemical modification
The two glycoproteins of E1 and E2 on Sindbis virus have been previously used for
structure characterization by NHS-Biotin reagent [16]. The biotinylation of only one E1
lysine residue along with seven E2 lysine residues indicated that E1 protein is buried by
E2 protein. Moreover, the E1 and E2 cysteine residues were labeled with iodoacetamide
to study how the disulfide bonds between the two structure proteins help maintain the
virus integrity [17]. Different Cys residues contained free sulfhydryl groups were labeled
at pH8.0 or pH 5.3 which means the virus surface structure will change at different pH
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environments. Here, we used a trifunctional reagent containing three moieties – a
maleimide group to bind cysteine residues containing free thiols, either a TAMRA
fluorescence molecule or a photoreactive crosslinker, and a biotin tag for capturing the
virus particle. The first generation reagent that we called Maleimide-TAMRA-Biotin
(MTB) probe is shown in Figure 3.1A. The included TAMRA molecule is a rhodamine
derivative fluorophore with Abs λmax of 557 nm and Em λmax of 583 nm. Maleimide
can react with the cysteine residues to a stable carbon-sulfur bond. We hypothesized that
the free thiols on Sindbis virus surface proteins would be the targets for us to label with
the MTB reagent. TAMRA serves as a fluorescent beacon that can detect the labeled
proteins after SDS-PAGE with a fluorescence imager. The MTB reagent was used as a
testing control of the experimental design, including the working ratio of reagent to virus
particles, the value of Multiplicity Of Infection (MOI), and the biotin capturing test. The
second generation reagent is Maleimide-LC-SDA-Biotin (MDB) which uses a
photocrosslinker instead of TAMRA group to crosslink proteins interacting with the virus
(Figure 3.1B). The photocrosslinker of diazirine can be activated by UV irradiation and
creates reactive carbine intermediate that can form covalent bonds through addition
reaction with any amino acid side chain or peptide backbone within the spacer arm
distance [18]. Thus, after crosslinking, we can use harsh wash conditions to remove most
of the non-specific binding proteins. In this thesis, we only discuss the method
development portion of the project by the first-generation MTB reagent.
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3.2 Materials and Methods

3.2.1 Cell culture and virus purification
Wt-Sindbis viruses (Toto64) were propagated in baby hamster kidney (BHK) cells
which were grown in MEM with 10% fetal bovine serum at 37°C and 5% CO2. Twenty
150mm culture dishes of 80% confluence BHK cells were infected at a multiplicity of
infection (MOI) of 10 Plaque Forming Unit (PFU)/cell and harvested 24 hour
post-infection. The harvested supernatant was centrifuged in a JA-14 Beckman rotor at
10,000 rpm for 20 min to remove cell debris from the solution. The supernatant was
loaded on top of 2 ml of 30% sucrose solution in PBS and centrifuged in Ti 50.2 rotor at
32,000 rpm for 2 hours at 4°C. After centrifugation, the supernatant was discarded and the
tubes placed on rotating table for 15 min. The virus solution was collected from the
bottom of tubes. The medium solution was replaced with sterile PBS by Ultrafree-4
centrifugal filter unit (100KDa, 4ml, Millipore). The virus solution was split into small
aliquots and stored at -80°C.

3.2.2 Plaque assay
Serial dilutions (10-fold) of virus were prepared in PBS containing 1% FBS plus 10
mM CaCl2 and 10 mM MgCl2. BHK cells were seeded in 6-well plates until 90%
confluence and propagated with 250μl of dilutions at room temperature for 1 hour. Then
MEM containing 5% FBS and 1% agarose was added. Cells were incubated at 37°C for
48 hours and the plaques were stained with neural red in PBS.
3.2.3 Maleimide-TAMRA-Biotin (MTB) reagent labeling
109 PFU/ml Sindbis virus in PBS, pH7.4 were adjusted to pH6 by slightly acidic
sterile PBS. Labeling of the virus was done with 1mM MTB reagent at 4°C overnight,
and the free reagent was removed by Zeba spin desalting columns, 7K MW (Thermo
scientific). The titer of labeled virus was determined by plaque assay.
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3.2.4 Western blotting
The labeled Sindbis virus particles were separated by SDS-PAGE and transferred
onto two PVDF membranes. Membrane was incubated in blocking buffer (10% BSA in
TBS with 0.05% Tween-20) for 1 h at room temperature and then incubated in blocking
buffer containing the 1:1000 dilution of avidin-horseradish peroxidase (HRP) at room
temperature for 1 hour or 1:500 dilution of mouse anti-E1-161 antibody (Gift from Dr.
Kuhn’s lab) at 4°C overnight. The membranes were then washed three times in TBS with
0.05% Tween-20 for 5min. The membrane incubated with avidin-HRP was directly
developed with HyGlo chemiluminescence reagent (Denville scientific, Metuchen, NJ).
The membrane containing the anti-E1-161 antibody was further incubated with
horseradish

peroxidase-conjugated

anti-mouse

IgG

antibody

(Cell

Signaling

Technologies) for 1 hour at room temperature. After several washes, the blot was
developed with HyGlo chemiluminescence reagent (Denville scientific, Metuchen, NJ).
3.2.5 BHK cells infection of MTB-labeled Sindbis virus
BHK cells in a 10 cm culture dish were infected with wt-SINV (Toto64) or
MTB-labeled SINV at MOI 15. First, the culture medium was discarded and the cells
washed with sterile PBS. Virus solution in 3ml of MEM was overlaid on the cells and
incubated on rocking platform at room temperature for 1 hour (the time needed for
viruses attach onto the cell surface). MEM containing 1% FBS was added into each plate
and incubated at 37°C for 1 hour (the time needed for viruses enter into cells). Finally,
infected cells were harvested by trypsin and washed with sterile PBS. The cell pellet was
stored at -80°C until future use.

3.2.6 Cell lysis, streptavidin agarose capture, trypsin digestion and Nu-Tip® C18
desalting
Cell pellet was resuspended in lysis buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
1% NP40] supplemented with 1x protease inhibitor (Tablet from Roche). Cells were
lysed by probe sonication on ice twice with a 20 second pulse and 10 second interval.
The supernatant containing soluble proteins was collected after centrifugation at 14000
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rpm for 10 minus. MTB-labeled SINV viruses were captured by Pierce® Streptavidin
agarose (Thermo Scientific) and further washed with lysis buffer. The virus-protein
complex was reduced in 50 mM ammonium bicarbonate containing 5 mM dithiothreitol
for 30 minus at 50 °C. The proteins were further alkylated in 15 mM iodoacetamide for 1
hour in the dark at room temperature and digested with 0.5 μg proteomics grade trypsin
(Sigma) in a total volume of 200 μl solution containing 50 mM ammonium bicarbonate
(pH 8.3) at 37℃ overnight. The tryptic peptides solution was acidified by Trifluoroacetic
acid (TFA). The Nu-Tip® C18 (Glygen Corp.) were prewetted by pipetting three times
with 100% Acetonitrile (ACN). The tips were equilibrated by pipetting ten times with
0.1% TFA. The peptides were bound to Nu-Tip by fully pipetting to a dead stop and
aspirating sample 20 cycles, and then washed tips with 0.1% TFA for 15 cycles. Fifty
microliters of 0.1%TFA/80% ACN were aspirated into a new sterile centrifuge tubes and
pipetted 20 times to elute peptides. The desalting peptides were dried by speedvac.
3.2.7 Mass spectrometry
The resulting peptides were resuspended in a solution containing 0.25% formic acid
(v/v) and analyzed using an Easy-nLC1000 (Thermo Scientific, San Jose, CA) coupled to a
hybrid mass spectrometer (LTQ-Orbitrap-Velos; Thermo Scientific, San Jose, CA). The
peptides were applied to an analytical column (75 μ m x 30 cm, 2.2 μ m,
ProntoPEARL-120-2.2-C18AQ beads (BISCHOFF chromatography) at ~200 nl/min, and
eluted using a gradient that ran from 5 to 30% of acetonitrile (0.1% formic acid) over 90
minutes. The LTQ-Orbitrap-Velos MS was operated in a data-dependent mode to switch
between MS and MS2 acquisitions. The MS survey scans were acquired over a full m/z
range of 300-2000 by the detector. The 20 most intense precursor ions were sequentially
isolated and subjected to collision induced dissociation (CID) in the linear ion trap. The
general mass spectrometric conditions were: ESI voltage - 2.8 kV; transfer capillary
temperature - 200 °C; and normalized collision energy - 35%.
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3.2.8 Computational analysis of mass spectra
The Excalibur MS raw files were searched against a mixed database containing
mouse plus Sindbis virus using SEQUEST algorithm on Proteome Discoverer (version
1.3, Thermo Scientific). The search parameters included a peptide mass tolerance of 10
ppm and the MS/MS tolerance of 0.8 Da. In the residues modification, the variable
modifications were set to +15.9949Da for the potential oxidation of methionine. The
static modification of cysteine residues of +57.0214Da was set due to the alkylation by
iodoacetamide. Searches were performed with full tryptic digestion and allowed a
maximum of two missed cleavages on the peptides. False discovery rates (FDR) were set
to 1% for each analysis.
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3.3 Results

3.3.1 Analysis of the working labeling ratio of Maleimide-TAMRA-Biotin (MTB)
reagent to Sindbis virus (SINV)
In order to determine whether the MTB-labeled SINV would maintain the viral
infectivity, we incubated different concentrations of MTB reagent with purified virus
particles. The concentration of MTB reagent was increased from 0.01 μM to a maximum
of 10mM MTB reagent. The negative control was the batch of viral particles without
labeling. Plaque assay was performed using each labeled virus sample to determine the
viral titer (Plaque Forming Unit/ml). The effect of virus labeling is shown in Figure 3.2.
The plot demonstrates that the infectivity was unaffected at the concentration of below
1mM MTB reagent label. With increased concentration beyond that point, the infectivity
significantly dropped by three orders of magnitude. In order to get the highest labeling
efficiency without affecting the virus pathogenic property, we have selected a range of
1mM to 5mM MTB reagent to test the labeling efficiency. The labeling result was first
tested by detecting the TAMRA fluorescence in gel (Figure 3.3). According to the gel
image, the fluorescence intensity appears darker after increasing the MTB labeling
concentration (Figure 3.3A). The same gel was stained by Coomassie Brilliant Blue and
showed equal amount of sample loading (Figure 3.3B). The infectivity analysis of the
five labeled virus samples was also performed by plaque assay (Figure 3.4). The plot
shows that the infectivity is unaffected up to MTB concentration of 2 mM. At 1mM of
MTB reagent, the infectivity is slightly reduced but still at the similar level with
non-labeled virus (0mM, negative control). Thus, the MTB reagent concentration for
each ~ 109 PFU SINV labeling was determined to be 1mM.
3.3.2 Analysis of the SINV labeling specificity by avidin and anti - SINV structure
protein antibody
The labeling of SINV by the 1mM MTB reagent was further tested for labeling
specificity by western blotting with avidin-HRP and the anti-E1 structure protein
antibody (E1-161, a gift from Kuhn lab). Since the labeled sites are supposed to occur on
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the virus surface, we expect that E1 and E2 virus surface structure proteins can be
detected at MW ~ 50KDa. In Figure 3.5, the blot against avidin-HRP shows a pattern of
multiple bands. In order to verify which bands correspond to E1/E2 proteins, we used
anti-E1 antibody to do the comparison. The E1 band is observed around the expected 50
kDa in both of MTB-labeled virus and unlabeled virus (negative control). In the
avidin-HRP blot, the 50kDa region also produced the second major detectable band
(Figure 3.5; indicated by red arrow). Due to the procedure of virus purification, some
of the proteins from culture medium, such as serum albumin, could be the detected
nonspecific non-virus contaminants. In our attempts to remove these, even the use of
100kDa MW cut-off spin column to remove the non-virus molecules still resulted in
detectable media proteins
3.3.3 Examination of capture efficiency of MTB-labeled SINV by streptavidin beads
One millimolar [mM] of MTB reagent has been determined as the working
concentration to label a batch of 109 PFU SINV, and the labeling efficiency has been
examined by western blotting using avidin-HRP and anti-E1 antibody (Figure 3.5). The
next logical step was the test of whether the labeled virus could be captured by
streptavidin agarose beads. After the labeling, we removed the free MTB reagent which
may interfere with the binding of MTB-labeled virus to streptavidin beads by Zeba
column (7kDa MW cut-off spin column) and dialysis. As demonstrated in Figure 3.6, the
sample eluted by boiling in SDS buffer showed an obvious TAMRA fluorescent band at
~50kDa. A light smear above the bands is likely due to different degrees of MTB
modification on E1/E2 proteins.
3.3.4 MS analysis of MTB labeled SINV infection
We first carried out an in vitro test to determine the optimal Multiplicity of Infection
(MOI), before the complete infection test. For this purpose, we mixed the BHK cells with
MTB-labeled SINV at MOI 5 and 15, lysed the mixture and captured the MTB-labeled
virus by streptavidin agarose beads. Non-labeled virus was used as a negative control.
The captured proteins were reduced and alkylated on the beads with 5mM DTT and
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15mM IAA, respectively. Trypsin was added for on-beads digestion. Tryptic peptides
were collected, desalted with C18 tips and analyzed by LC-MS. As shown in Table 3.1,
there were 968 mouse proteins with two Sindbis virus proteins (Capsid and E2 protein)
identified from the mixture at MOI 15. Only one Sindbis virus capsid and a total of 924
proteins were identified from the mixture at MOI 5. Only virus capsid was present in the
negative control at MOI 5, which we consider as a non-specific identification. Thus, MOI
15 was determined to be the minimum MOI value for future infection.
For the complete infection test, labeled virus was used to infect the BHK cells at
MOI 15 for 45 minute at 37°C. The cells were similarly harvested, lysed and captured
onto streptavidin agarose beads. There were 557 total proteins with one virus E1-E2
heterodimer identified by the LC-MS/MS analysis (Table 3.2). Six peptides correspond
to the E1-E2 heterodimer in the list, which increases the likelihood of accurate virus
protein identification. As the result of these optimization efforts, the 1mM MTB- labeled
virus retains similar infectivity of BHK cells to that of unlabeled virus, and can be
captured by streptavidin at MOI 15.
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3.4 Discussion

3.4.1 The trifunctional reagent provides an efficient way to modify model virus for
virus-host early entry study
We used the Maleimide-TAMRA-Biotin (MTB) reagent to successfully modify the
surface structure proteins of Sindbis virus. After the removal of protein identified in the
negative control, there were 199 proteins identified post-infection by LC-MS/MS
analysis. Those proteins were further classified by Ingenuity Pathway Analysis (IPA;
http://www.ingenuity.com/products/ipa). Since our study is focused on the early entry
stage of the virus, the infection time was limited to only 45 minutes. We identified
several proteins known to be involved in the pathway of virus entry. For instance, the
proteins involved in clathrin-mediated endocytosis signaling are transferrin receptor,
integrin, actin-related proteins (ACTR2, ACTR3, ARPC1B and ARPC4), transporter
proteins (AP2M1 and AP2A1) and SH3GLB1, which is an enzyme involved in
endocytosis. Proteins in caveolar-mediated endocytosis signaling, integrin signaling, and
FcƳ receptor-mediated phagocytosis in macrophages and monocytes were also identified
in the list. When we look into the disease and bio-functions category, there were 40
proteins identified that related to the viral infection, such as transferrin receptor (TFRC),
which have been reported to help the virus entry by endocytic pathway [19]. Moreover,
the identified protein PML plays a role in antiviral defense mechanism [20], and KPBN1
functions as the HIV integration factor [4]. Thus, we conclude that the 1mM
MTB-labeled Sindbis virus can truly offer a detailed examination of the infection
processes of BHK cells.
3.4.2 The limitation of virus identification
According to the previous studies, we hypothesized that virus surface proteins were
ideal targets of chemical modification for the virus early entry study. More identification
number of virus peptides provides higher confidence for the successful capturing
condition. Our analysis identified six E1-E2 heterodimer peptides in the MS list. We tried
to increase the virus peptides identification number by utilizing harsher lysis conditions
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(such as 8M Urea or 2% SDS). The harsher lysis conditions were used to denature the
virus structure more completely and we supposed that the denatured viruses can be
digested by trypsin more efficiently. However, the tested conditions were not successful
in increasing the peptides identification number. The MTB labeling may cause some
disruption during trypsin digestion. It is possible that MTB labeling covered multiple
tryptic sites, thus resulting in limited tryptic peptides identification. Increasing the MOI
of infection or modifying the structure of the reagent (e.g. spacer arm length) might be
the solutions.
3.4.3 Future direction
In this study, we identified 556 BHK cell proteins with one Sindbis virus structure
protein in the MTB-labeled virus sample. Even we identified several proteins which were
related to the virus infection pathways, the optimal result we expected was not with this
high number of proteins identification. There are 358 BHK proteins overlapped with
non-labeled control sample which means the non-specific capturing is high. The reason
may cause by the non-specific binding on the agarose beads. MTB is the first generation
reagent that we used for tracing the labeling efficiency by TAMRA fluorescence. In order
to address the problem of non-specific protein binding, the next generation of our
trifunctional reagent substitutes the TAMRA group with an NHS-Diazirine (SDA)
crosslinker. The UV-activated photocrosslinker targets specific amino acid groups (e.g.,
lysine or cysteine) at the correct distance to capture virus and host protein interactions
[21]. After activating the photocrosslinker to “fix” the interactome, any virus binding
partners can be retained even after several harsh wash conditions to remove the
nonspecific binding proteins. Such an approach should result in more accurate
identification of specific host proteins involved in virus infection.
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Figures

(A)

(B)

Figure 3.1 Maleimide-TAMRA-Biotin (MTB) and Maleimide- LC-SDA-Biotin
(MDB) reagents. The two trifunctional reagents used for Sindbis virus modification
contain a maleimide moiety for coupling to ligands via free thiol group on cysteine
residues, a biotin group for affinity purification, and rather A) TAMRA fluorophore for
tracing the labeling efficiency or B) photocrosslinker of diazirine for virus-host
interacting proteins crosslinking. TAMRA: tetramethylrhodamine.
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Figure 3.2 Plot of the plaque forming units (PFU) of MTB labeled Sindbis virus.
X-axis indicates the concentration of MTB reagent. The unlabeled Sindbis virus serves as
a control (Green spot). The range indicated by red oval was chosen for further
examination.
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Figure 3.3 Analysis of Maleimide-TAMRA-Biotin (MTB) reagent labeling efficiency
by gel image. Sindbis virus were labeled by 0mM (Control), 1, 2, 3, 4 and 5mM of MTB
reagent and loaded onto SDS-PAGE. (A) TAMRA fluorescence signal was visualized by
Typhoon imager. (B) The same gel of (A), but was stained with Commassie Blue for total
protein detection.
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Figure 3.4 Plot of the plaque forming units (PFU) of 0-5mM MTB labeled Sindbis
virus. BHK cells seeded in 6-well plates were infected with MTB-labeled Sindbis virus
and incubated with 1% agar medium for 2 days at 37°C, 5% CO2. The plaques were
stained by neural red for 4 hours and counted for virus amount released into the medium.
X-axis indicates the concentration of MTB reagent. “Fresh” indicates the original viral
titer from -80°C stock. First test: Red square ; Second test: Green triangle .
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Figure 3.5 Western blotting analysis of the MTB labeled Sindbis virus. Sindbis virus
was labeled by 1mM MTB reagent at 4°C overnight and the labeled proteins examined by
Western Blot using avidin-HRP and sindbis virus anti-E1 antibody (E1-161). Unlabeled
virus serves as a negative control. Virus E1 protein was detected by Western Blot against
E1 protein around the predicted molecular weight of 50kDa. The likely virus E1/E2
proteins are indicated by the red arrow on the membrane blotted using avidin-HRP. The
major band detected by avidin-HRP is likely the bovine serum albumin from culture
medium.
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Figure 3.6 Gel image of TAMRA fluorescence signal after MTB-labeled Sindbis
virus were captured by streptavidin beads. Sindbis virus was labeled by 1mM MTB
reagent and captured with streptavidin agarose beads. The captured virus was eluted by
boiling in SDS sample buffer and visualized for TAMRA fluorescence with Typhoon
imager. 1% of total input volume and flowthrough (FT), as well as 100% of elution were
loaded into gel. Neg: unlabeled Sindbis virus was a negative control.
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Tables

Table 3.1 LC-MS/MS analysis summary of the in vitro streptavidin-captured
Sindbis virus proteins and peptides

Table 3.2 LC-MS analysis summary of the streptavidin-captured Sindbis virus
proteins and peptides after complete in situ infection

